<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39275298</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2072-6643</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>17</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Nutrients</Title><ISOAbbreviation>Nutrients</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Food Supplement Based on Monacolins, γ-Oryzanol, and γ-Aminobutyric Acid in Mild Dyslipidemia: A Randomized, Double-Blind, Parallel-Armed, Placebo-Controlled Clinical Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2983</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/nu16172983</ELocationID><Abstract><AbstractText>The risk of cardiovascular disease (CVD) is approximately doubled in subjects with hypercholesterolemia compared to those with normal blood cholesterol levels. Monacolin K (MK), the main active substance in rice fermented by the <i>Monascus purpureus</i>, acts on cholesterol metabolism. Rice also contains other bioactive compounds such as γ-oryzanol (OZ) and γ-aminobutyric acid (GABA). In a randomized, placebo-controlled, double-blind trial, the efficacy and tolerability of a food supplement (FS) based on an ingredient standardized to contain monacolins (4.5%), OZ, and GABA were evaluated in subjects with mild dyslipidemia. For the duration of the trial, enrolled subjects (<i>n</i> = 44, each group) received the FS or placebo and were instructed to use an isocaloric diet. Compared to the placebo group, after a 3 months of the FS, the mean low-density lipoprotein cholesterol and mean TC values were reduced by 19.3 and 8.3%, respectively, while the mean high-density lipoprotein cholesterol value increased by 29.3%. On average, the subjects shifted from very high to moderate CVD risk. Glucose metabolism and hepatic and renal parameters did not change after the treatment and no adverse events were reported. Guidelines to handle hypercholesterolemia with food supplements in specific clinical settings are needed to better manage mild dyslipidemia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Lellis</LastName><ForeName>Lorenza Francesca</ForeName><Initials>LF</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morone</LastName><ForeName>Maria Vittoria</ForeName><Initials>MV</Initials><Identifier Source="ORCID">0009-0000-0810-8460</Identifier><AffiliationInfo><Affiliation>Department of Experimental Medicine, Section of Microbiology and Clinical Microbiology, University of Campania "L. Vanvitelli", 80138 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buccato</LastName><ForeName>Daniele Giuseppe</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordara</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Medicine, University of Milano-Bicocca, 20126 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larsen</LastName><ForeName>Danaè S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>School of Chemical Sciences, The University of Auckland, Auckland 1010, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ullah</LastName><ForeName>Hammad</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9437-676X</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccinocchi</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Level 1 Medical Director Anaesthesia and Resuscitation A. U. O. Luigi Vanvitelli, Via Santa Maria di Costantinopoli, 80138 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Piccinocchi</LastName><ForeName>Gaetano</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3095-2198</Identifier><AffiliationInfo><Affiliation>Comegen S.c.S., Società Cooperativa Sociale di Medici di Medicina Generale, Viale Maria Bakunin 41, 80125 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balaji</LastName><ForeName>Paulraj</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6839-4785</Identifier><AffiliationInfo><Affiliation>PG and Research Centre in Biotechnology, MGR College, Hosur 635130, TN, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldi</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2877-9445</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Minno</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8084-9976</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131 Naples, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CEINGE-Biotecnologie Avanzate, Via Gaetano Salvatore 486, 80145 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>El-Seedi</LastName><ForeName>Hesham R</ForeName><Initials>HR</Initials><Identifier Source="ORCID">0000-0002-2519-6690</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Faculty of Science, Islamic University of Madinah, Madinah 42351, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sacchi</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-6199-0074</Identifier><AffiliationInfo><Affiliation>Applied Statistic Unit, Department of Earth and Environmental Sciences, University of Pavia, Viale Taramelli 24, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daglia</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4870-7713</Identifier><AffiliationInfo><Affiliation>Department of Pharmacy, University of Naples "Federico II", Via D. Montesano 49, 80131 Naples, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Research Center for Food Nutrition and Safety, Jiangsu University, Zhenjiang 212013, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Nutrients</MedlineTA><NlmUniqueID>101521595</NlmUniqueID><ISSNLinking>2072-6643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>SST9XCL51M</RegistryNumber><NameOfSubstance UI="C013172">gamma-oryzanol</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010666">Phenylpropionates</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9LHU78OQFD</RegistryNumber><NameOfSubstance UI="D008148">Lovastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008076">Cholesterol, HDL</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019587" MajorTopicYN="Y">Dietary Supplements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050171" MajorTopicYN="Y">Dyslipidemias</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010666" MajorTopicYN="Y">Phenylpropionates</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="Y">gamma-Aminobutyric Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008148" MajorTopicYN="N">Lovastatin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="N">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008076" MajorTopicYN="N">Cholesterol, HDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">mild dyslipidemia</Keyword><Keyword MajorTopicYN="N">monacolin K</Keyword><Keyword MajorTopicYN="N">randomized clinical trial</Keyword><Keyword MajorTopicYN="N">red yeast rice</Keyword><Keyword MajorTopicYN="N">γ-aminobutyric acid</Keyword><Keyword MajorTopicYN="N">γ-oryzanol</Keyword></KeywordList><CoiStatement>A.D.M. was employed by CEINGE-Biotecnologie Avanzate. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>15</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>10</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>14</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39275298</ArticleId><ArticleId IdType="pmc">PMC11397197</ArticleId><ArticleId IdType="doi">10.3390/nu16172983</ArticleId><ArticleId IdType="pii">nu16172983</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Muller-Nordhorn J., Binting S., Roll S., Willich S.N. An update on regional variation in cardiovascular mortality within Europe. Eur. Heart J. 2008;29:1316–1326. doi: 10.1093/eurheartj/ehm604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehm604</ArticleId><ArticleId IdType="pubmed">18256043</ArticleId></ArticleIdList></Reference><Reference><Citation>Perk J., De Backer G., Gohlke H., Graham I., Reiner Z., Verschuren M., Albus C., Benlian P., Boysen G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur. Heart J. 2012;33:1635–1701.</Citation><ArticleIdList><ArticleId IdType="pubmed">22555213</ArticleId></ArticleIdList></Reference><Reference><Citation>Karr S. Epidemiology and management of hyperlipidemia. Am. J. Manag. Care. 2017;23:S139–S148.</Citation><ArticleIdList><ArticleId IdType="pubmed">28978219</ArticleId></ArticleIdList></Reference><Reference><Citation>Buzzelli L., Segreti A., Di Gioia D., Lemme E., Squeo M.R., Nenna A., Di Gioia G. Alternative lipid lowering strategies: State-of-the-art review of red yeast rice. Fitoterapia. 2024;172:105719. doi: 10.1016/j.fitote.2023.105719.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fitote.2023.105719</ArticleId><ArticleId IdType="pubmed">37931717</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffin L.J., Bruemmer D., Garcia M., Brennan D.M., McErlean E., Jacoby D.S., Michos E.D., Ridker P.M., Wang T.Y., Watson K.E., et al. Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements on lipids and inflammatory biomarkers. J. Am. Coll. Cardiol. 2023;81:1–12. doi: 10.1016/j.jacc.2022.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2022.10.013</ArticleId><ArticleId IdType="pubmed">36351465</ArticleId></ArticleIdList></Reference><Reference><Citation>Banach M., Catapano A.L., Cicero A.F., Escobar C., Foger B., Katsiki N., Latkovskis G., Rakowski M., Reiner Z., Sahebkar A., et al. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel. Pharmacol. Res. 2022;183:106370. doi: 10.1016/j.phrs.2022.106370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2022.106370</ArticleId><ArticleId IdType="pubmed">35901940</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicero A.F.G., Fogacci F., Zambon A. Red yeast rice for hypercholesterolemia: JACC focus seminar. J. Am. Coll. Cardiol. 2021;77:620–628. doi: 10.1016/j.jacc.2020.11.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.11.056</ArticleId><ArticleId IdType="pubmed">33538260</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokumai T., Ito J., Kobayashi E., Shimizu N., Hashimoto H., Eitsuka T., Miyazawa T., Nakagawa K. Comparison of blood profiles of γ -oryzanol and ferulic acid in rats after oral intake of γ-oryzanol. Nutrients. 2019;11:1174. doi: 10.3390/nu11051174.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11051174</ArticleId><ArticleId IdType="pmc">PMC6567117</ArticleId><ArticleId IdType="pubmed">31130653</ArticleId></ArticleIdList></Reference><Reference><Citation>Roohinejad S., Omidizadeh A., Mirhosseini H., Saari N., Mustafa S., Yusof R.M., Hussin A.S.M., Hamid A., Manap M.Y.A. Effect of pre-germination time of brown rice on serum cholesterol levels of hypercholesterolaemic rats. J. Sci. Food. Agric. 2010;90:245–251. doi: 10.1002/jsfa.3803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jsfa.3803</ArticleId><ArticleId IdType="pubmed">20355038</ArticleId></ArticleIdList></Reference><Reference><Citation>Derosa G., Maffioli P., D’Angelo A., Russo R. Effects of a nutraceutical combination of monacolin, gamma-oryzanol and gamma-aminobutyric acid on lipid profile and C-reactive protein in mice. Arch. Med. Sci. 2019;15:792–796. doi: 10.5114/aoms.2018.75193.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2018.75193</ArticleId><ArticleId IdType="pmc">PMC6524184</ArticleId><ArticleId IdType="pubmed">31110547</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T.J., Lien A.S., Chen J.L., Lin C.H., Yang Y.S., Yang S.H. A randomized clinical efficacy trial of red yeast rice (Monascus pilosus) against hyperlipidemia. Am. J. Chin. Med. 2019;47:323–335. doi: 10.1142/S0192415X19500150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1142/S0192415X19500150</ArticleId><ArticleId IdType="pubmed">30871361</ArticleId></ArticleIdList></Reference><Reference><Citation>Commission Regulation (EU) 2022/860 of 1 June 2022 Amending Annex III to Regulation (EC) No 1925/2006 of the European Parliament and of the Council as Regards Monacolins from Red Yeast Rice (Text with EEA Relevance)  [(accessed on 24 June 2024)].  Available online:  https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32022R0860&amp;qid=1719245311125.</Citation></Reference><Reference><Citation>Baldi A. The Beneficial Effect on Cardiovascular Function of a Food Supplement Based on Red Yeast Rice (Monacolin K), Gamma-Oryzanol from Rice Bran, and Gamma-Aminobutyric Acid.  [(accessed on 6 July 2024)].  Available online:  https://www.isrctn.com/ISRCTN90678255.</Citation></Reference><Reference><Citation>Sanità, the Italian National Institute of Health (ISD). Il Progetto Cuore.  [(accessed on 6 July 2024)].  Available online:  https://www.cuore.iss.it/</Citation></Reference><Reference><Citation>Appel L.J. The effects of dietary factors on blood pressure. Cardiol. Clin. 2017;35:197–212. doi: 10.1016/j.ccl.2016.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccl.2016.12.002</ArticleId><ArticleId IdType="pubmed">28411894</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiavaroli L., Viguiliouk E., Nishi S.K., Blanco Mejia S., Rahelic D., Kahleova H., Salas-Salvadó J., Kendall C.W., Sievenpiper J.L. DASH dietary pattern and cardiometabolic outcomes: An umbrella review of systematic reviews and meta-analyses. Nutrients. 2019;11:338. doi: 10.3390/nu11020338.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11020338</ArticleId><ArticleId IdType="pmc">PMC6413235</ArticleId><ArticleId IdType="pubmed">30764511</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanità, the Italian Ministry of Health (MDS) and The Italian National Institute of Health (ISD). VigiErbe.  [(accessed on 7 April 2024)].  Available online:  www.vigierbe.</Citation></Reference><Reference><Citation>Bates D., Mächler M., Bolker B., Walker S. Fitting Linear Mixed-Effects Models Using lme4. arXiv. 20141406.5823</Citation></Reference><Reference><Citation>R.C. Team  R: A Language and Environment for Statistical Computing. 2022.  [(accessed on 4 June 2024)].  Available online:  http://www.r-project.org/index.html.</Citation></Reference><Reference><Citation>Calvert M., Blazeby J., Altman D.G., Revicki D.A., Moher D., Brundage M.D., Group C.P. Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA. 2013;309:814–822. doi: 10.1001/jama.2013.879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.879</ArticleId><ArticleId IdType="pubmed">23443445</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta S., Johansson A., Drake I. Diet and lifestyle factors and risk of atherosclerotic cardiovascular disease—A prospective cohort study. Nutrients. 2021;13:3822. doi: 10.3390/nu13113822.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13113822</ArticleId><ArticleId IdType="pmc">PMC8622601</ArticleId><ArticleId IdType="pubmed">34836078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari R., Lüscher T.F. Reincarnated medicines: Using out-dated drugs for novel indications. Eur. Heart J. 2016;37:2571–2576. doi: 10.1093/eurheartj/ehw051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw051</ArticleId><ArticleId IdType="pubmed">26957422</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence G.D. Dietary fats and health: Dietary recommendations in the context of scientific evidence. Adv. Nutr. 2013;4:294–302. doi: 10.3945/an.113.003657.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/an.113.003657</ArticleId><ArticleId IdType="pmc">PMC3650498</ArticleId><ArticleId IdType="pubmed">23674795</ArticleId></ArticleIdList></Reference><Reference><Citation>Astrup A., Magkos F., Bier D.M., Brenna J.T., de Oliveira Otto M.C., Hill J.O., King J.C., Mente A., Ordovas J.M., Volek J.S., et al. Saturated fats and health: A reassessment and proposal for food-based recommendations: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2020;76:844–857. doi: 10.1016/j.jacc.2020.05.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.05.077</ArticleId><ArticleId IdType="pubmed">32562735</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks F.M., Lichtenstein A.H., Wu J.H., Appel L.J., Creager M.A., Kris-Etherton P.M., Miller M., Rimm E.B., Rudel L.L., Robinson J.G., et al. Dietary fats and cardiovascular disease: A presidential advisory from the American Heart Association. Circulation. 2017;136:e1–e23. doi: 10.1161/CIR.0000000000000510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000510</ArticleId><ArticleId IdType="pubmed">28620111</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidding S.S., Allen N.B. Cholesterol and atherosclerotic cardiovascular disease: A lifelong problem. J. Am. Heart Assoc. 2019;8:e012924. doi: 10.1161/JAHA.119.012924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.119.012924</ArticleId><ArticleId IdType="pmc">PMC6585375</ArticleId><ArticleId IdType="pubmed">31137996</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdullah S.M., Defina L.F., Leonard D., Barlow C.E., Radford N.B., Willis B.L., Rohatgi A., McGuire D.K., de Lemos J.A., Grundy S.M., et al. Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease: Results from the Cooper Center Longitudinal Study. Circulation. 2018;138:2315–2325. doi: 10.1161/CIRCULATIONAHA.118.034273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.034273</ArticleId><ArticleId IdType="pubmed">30571575</ArticleId></ArticleIdList></Reference><Reference><Citation>Muntner P., Lee F., Astor B.C. Association of high-density lipoprotein cholesterol with coronary heart disease risk across categories of low-density lipoprotein cholesterol: The atherosclerosis risk in communities study. Am. J. Med. Sci. 2011;341:173–180. doi: 10.1097/MAJ.0b013e3181f97e4a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MAJ.0b013e3181f97e4a</ArticleId><ArticleId IdType="pubmed">21042169</ArticleId></ArticleIdList></Reference><Reference><Citation>Danese M.D., Gleeson M., Kutikova L., Griffiths R.I., Khunti K., Seshasai S.R.K., Ray K.K. Management of lipid-lowering therapy in patients with cardiovascular events in the UK: A retrospective cohort study. BMJ Open. 2017;7:e013851. doi: 10.1136/bmjopen-2016-013851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-013851</ArticleId><ArticleId IdType="pmc">PMC5566621</ArticleId><ArticleId IdType="pubmed">28495810</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruscica M., Ferri N., Banach M., Sirtori C.R., Corsini A. Side effects of statins: From pathophysiology and epidemiology to diagnostic and therapeutic implications. Cardiovasc. Res. 2022;118:3288–3304. doi: 10.1093/cvr/cvac020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cvr/cvac020</ArticleId><ArticleId IdType="pubmed">35238338</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter P.M., Hegele R.A. Functional foods and dietary supplements for the management of dyslipidaemia. Nat. Rev. Endocrinol. 2017;13:278–288. doi: 10.1038/nrendo.2016.210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrendo.2016.210</ArticleId><ArticleId IdType="pubmed">28133369</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoeneck M., Iggman D. The effects of foods on LDL cholesterol levels: A systematic review of the accumulated evidence from systematic reviews and meta-analyses of randomized controlled trials. Nutr. Metab. Cardiovasc. Dis. 2021;31:1325–1338. doi: 10.1016/j.numecd.2020.12.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2020.12.032</ArticleId><ArticleId IdType="pubmed">33762150</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicero A.F., Ferroni A., Ertek S. Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. Expert Opin. Drug Saf. 2012;11:753–766. doi: 10.1517/14740338.2012.705827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14740338.2012.705827</ArticleId><ArticleId IdType="pubmed">22788832</ArticleId></ArticleIdList></Reference><Reference><Citation>Verhoeven V., Lopez Hartmann M., Remmen R., Wens J., Apers S., Van Royen P. Red yeast rice lowers cholesterol in physicians—A double blind, placebo controlled randomized trial. BMC Complement. Altern. Med. 2013;13:178. doi: 10.1186/1472-6882-13-178.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6882-13-178</ArticleId><ArticleId IdType="pmc">PMC3726474</ArticleId><ArticleId IdType="pubmed">23866314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicero A.F., Derosa G., Parini A., Maffioli P., D’Addato S., Reggi A., Giovannini M., Borghi C. Red yeast rice improves lipid pattern, high-sensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr. Res. 2013;33:622–628. doi: 10.1016/j.nutres.2013.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nutres.2013.05.015</ArticleId><ArticleId IdType="pubmed">23890351</ArticleId></ArticleIdList></Reference><Reference><Citation>Minamizuka T., Koshizaka M., Shoji M., Yamaga M., Hayashi A., Ide K., Ide S., Kitamoto T., Sakamoto K., Hattori A., et al. Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial. Asia Pac. J. Clin. Nutr. 2021;30:424–435.</Citation><ArticleIdList><ArticleId IdType="pubmed">34587702</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong X., Wang P., Li X., Zhang Y., Li S. The effects of red yeast rice dietary supplement on blood pressure, lipid profile, and C-reactive protein in hypertension: A systematic review. Crit. Rev. Food Sci. Nutr. 2017;57:1831–1851. doi: 10.1080/10408398.2015.1018987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10408398.2015.1018987</ArticleId><ArticleId IdType="pubmed">26167669</ArticleId></ArticleIdList></Reference><Reference><Citation>EFSA Panel. Younes M., Aggett P., Aguilar F., Crebelli R., Dusemund B., Filipič M., Frutos M.J., Galtier P., Gott D., et al. Scientific opinion on the safety of monacolins in red yeast rice. EFSA J. 2018;16:e05368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7009499</ArticleId><ArticleId IdType="pubmed">32626016</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding J., Ulanov A.V., Dong M., Yang T., Nemzer B.V., Xiong S., Zhao S., Feng H. Enhancement of gama-aminobutyric acid (GABA) and other health-related metabolites in germinated red rice (Oryza sativa L.) by ultrasonication. Ultrason. Sonochem. 2018;40:791–797. doi: 10.1016/j.ultsonch.2017.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ultsonch.2017.08.029</ArticleId><ArticleId IdType="pubmed">28946487</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X.-M., Shen X.-H., Duan Z.-W., Guo S.-R. Advances on the pharmacological effects of red yeast rice. Chin. J. Nat. Med. 2011;9:161–166.</Citation></Reference><Reference><Citation>Legesse D.H., Fan C., Teng J., Zhuang Y., Howard R.J., Noviello C.M., Lindahl E., Hibbs R.E. Structural insights into opposing actions of neurosteroids on GABA(A) receptors. Nat. Commun. 2023;14:5091. doi: 10.1038/s41467-023-40800-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40800-1</ArticleId><ArticleId IdType="pmc">PMC10444788</ArticleId><ArticleId IdType="pubmed">37607940</ArticleId></ArticleIdList></Reference><Reference><Citation>Thayer J.F., Lane R.D. Claude Bernard and the heart–brain connection: Further elaboration of a model of neurovisceral integration. Neurosci. Biobehav. Rev. 2009;33:81–88. doi: 10.1016/j.neubiorev.2008.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2008.08.004</ArticleId><ArticleId IdType="pubmed">18771686</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>